Arca
Skip to content
Tools
Tools

Label Changes: Vyleesi (bremelanotide acetate)

A drug's label (its prescribing information) is revised many times after approval: new warnings, new uses, new doses. DailyMed keeps every version. Pick a drug to see them all and what changed between any two.

Every version of the Vyleesi label DailyMed has published, from Cosette Pharmaceuticals, Inc., and what changed between any two of them, section by section. Current label on DailyMed.

  • Versions on DailyMed: 2
  • Sections changed, version 1 to 2: 3

What changed from version 1 to version 2

Nov 18, 2025 to Nov 9, 2026, as published on DailyMed. Added text is underlined in green, removed text struck through in red.
  1. Use in specific populationsChanged · 140 words added, 70 removed
  2. Patient counseling informationChanged · 34 words added, 55 removed
  3. Patient informationChanged · 990 words added, 1,060 removed

Use in specific populations

Changed140 words added, 70 removed
1 unchanged line
8.1 Pregnancy
Pregnancy Exposure Registry
There will be a pregnancy exposure registry that monitors pregnancy outcomes in women exposed to VYLEESI during pregnancy. Pregnant women exposed to VYLEESI and healthcare providers are encouraged to call the VYLEESI Pregnancy Exposure Registry at (800) 922-1038.
Risk Summary
11 unchanged lines
Risk Summary
There is no information on the presence of bremelanotide or its metabolites in human milk, the effects on the breastfed infant, or the effects on milk production.
Bremelanotide is transferred into breast milk in clinically insignificant amounts. In a clinical lactation study, following subcutaneous administration of a single 1.75 mg dose to 10 healthy lactating adult women between 10 days and 6 months postpartum, the mean total amount of bremelanotide present in breast milk over 24 hours was estimated to be 0.000152 mg. The relative infant dose was 0.132% of the weight-adjusted maternal dose. The concentration of bremelanotide in breast milk was not measurable (< 1 ng/mL) at 24-hours post-dose in all milk samples. The effects of bremelanotide on breastfed infants were not evaluated in the lactation study; however, effects on the breastfed infant are not expected based on the clinically insignificant amount transferred into breast milk. There are no available data on the effects of bremelanotide on milk production.
The developmental and health benefits of breastfeeding should be considered along with the mother's clinical need for VYLEESI and any potential adverse effects on the breastfed childinfant from VYLEESI or from the underlying maternal condition.
8.3 Females and Males of Reproductive Potential
10 unchanged lines

Patient counseling information

Changed34 words added, 55 removed
9 unchanged lines
Females of Reproductive Potential
Advise patients to use effective contraception while taking VYLEESI and to discontinue VYLEESI if pregnancy is suspected. Advise pregnant patients that there is a pregnancy registry that monitors pregnancy outcomes in women exposed to VYLEESI during pregnancy [see Use in Specific Populations ( 8.1, 8.3)].
Advise patients to use effective contraception while taking VYLEESI and to discontinue VYLEESI if pregnancy is suspected. [see Use in Specific Populations ( 8.1, 8.3)].
Marketed By: Cosette Pharmaceuticals, Inc. South PlainfieldBridgewater, NJ 0708008807
VYLEESI is a registered trademark of Cosette Pharmaceuticals, Inc.
© 20242026 Cosette Pharmaceuticals, Inc. All rights reserved.
8-0897CP1 Rev. 03/2024
8-0897CP2 Rev. 10/2024

Patient information

Changed990 words added, 1,060 removed
PATIENT INFORMATION
VYLEESI® (vahy-lee-see)
(bremelanotide injection)
for subcutaneous use
What is VYLEESI?
VYLEESI is a prescription medicine used to treat hypoactive (low) sexual desire disorder (HSDD) in women who have not gone through menopause, who have not had problems with low sexual desire in the past, and who have low sexual desire no matter the type of sexual activity, the situation, or the sexual partner. Women with HSDD have low sexual desire that is troubling to them. Their low sexual desire is not due to:
a medical or mental health problem
problems in the relationship
medicine or other drug use
VYLEESI is not for the treatment of HSDD in women who have gone through menopause or in men.
VYLEESI is not for use to improve sexual performance.
VYLEESI is not for use in children.
Do not use VYLEESI if you have:
high blood pressure that is not controlled (uncontrolled hypertension)
known heart (cardiovascular) disease
Before using VYLEESI, tell your healthcare provider about all of your medical conditions, including if you:
have high blood pressure.
have heart problems.
have kidney problems.
have liver problems. are pregnant or plan to become pregnant. It is not known if VYLEESI will harm your unborn baby. Women who can become pregnant should use effective birth control during treatment with VYLEESI. Talk to your healthcare provider about birth control choices that may be right for you during this time. Stop using VYLEESI and tell your healthcare provider right away if you become pregnant or think you might be pregnant during treatment with VYLEESI.
are breastfeeding or plan to breastfeed. Talk with your healthcare provider about the best way to feed your baby if you use VYLEESI.
Tell your healthcare provider about all the medicines you take, including prescription and over-the-counter medicines, vitamins, and herbal supplements. VYLEESI may affect the way other medicines work, and other medicines may affect the way VYLEESI works.
Know the medicines you take. Keep a list of them to show your healthcare provider and pharmacist each time you get a new medicine.
How should I use VYLEESI?
See the detailed “Instructions for Use” that comes with VYLEESI for information on how to prepare and inject a dose of VYLEESI. Talk to your healthcare provider or pharmacist if you have any questions.
Use VYLEESI exactly as prescribed by your healthcare provider.
VYLEESI comes in an autoinjector that you or your caregiver may use at home to give injections.
VYLEESI is given as an injection under the skin (subcutaneous injection), in your thighs or stomach area (abdomen).
Inject VYLEESI at least 45 minutes before you think that you will begin sexual activity.
Do not inject more than 1 dose of VYLEESI within 24 hours of your last dose.
Do not inject more than 8 doses of VYLEESI within a month.
Tell your healthcare provider if your symptoms of HSDD have not improved after you have used VYLEESI for 8 weeks.
What are the possible side effects of VYLEESI?
VYLEESI can cause serious side effects, including:
Temporary increase in blood pressure and decrease in heart rate: An increase in blood pressure and decrease in heart rate can happen shortly after you inject VYLEESI. These changes usually go away within 12 hours after your injection. Increases in blood pressure and an increased risk of heart (cardiovascular) problems can happen if you use VYLEESI more often than prescribed by your healthcare provider. See “How should I use VYLEESI?”
Darkening of the skin on certain parts of the body (focal hyperpigmentation) including the face, gums (gingiva) and breast. The chance of darkening of the skin is increased in people with darker skin color. The chance of darkening of the skin is higher if VYLEESI is used every day. Darkening of the skin may not go away, even after you stop using VYLEESI. Tell your healthcare provider if you have any concerns about changes to your skin.
Nausea. Nausea is common and can also be severe. Nausea most commonly happens after the first VYLEESI injection but can also happen after any dose of VYLEESI. The nausea usually lasts for about 2 hours but can last longer in some people. The nausea usually goes away by itself. Tell your healthcare provider if you have nausea that is severe or does not go away. Pre-treatment with the anti-nausea medicine ondansetron was not found to be effective to inhibit or reduce the nausea and is not recommended. Your healthcare provider may prescribe anti-nausea medicine for you to take after nausea occurs.
The most common side effects of VYLEESI include:
flushing
injection site reactions
headache
vomiting
cough
fatigue
hot flush
tingling
dizziness
nasal congestion
These are not all the possible side effects of VYLEESI.
Call your doctor for medical advice about side effects. You may report side effects to FDA at 1-800-FDA-1088.
How should I store VYLEESI?
Store at or below 77°F (25°C).
Do not freeze.
Protect from light.
Keep VYLEESI and all medicines out of the reach of children.
General information about the safe and effective use of VYLEESI.
Medicines are sometimes prescribed for purposes other than those listed in a Patient Information leaflet. Do not use VYLEESI for a condition for which it was not prescribed. Do not give VYLEESI to other people, even if they have the same symptoms you have. It may harm them.
You can ask your healthcare provider or pharmacist for information about VYLEESI that is written for health professionals.
What are the ingredients in VYLEESI?
Active ingredient: bremelanotide
Inactive ingredients: 2.5% glycerin, sterile water for injection, and hydrochloric acid or sodium hydroxide is added to adjust the pH
Marketed By: Cosette Pharmaceuticals, Inc.
VYLEESI is a registered trademark of Cosette Pharmaceuticals, Inc.
©2024 Cosette Pharmaceuticals, Inc. All rights reserved.
For more information, go to www.VYLEESI.com or call Cosette Pharmaceuticals, Inc. at the toll-free number 1-800-922-1038.
This Patient Information has been approved by the U.S. Food and Drug Administration | Revised: 0310/20242026
PATIENT INFORMATION VYLEESI ® (vahy-lee-see) (bremelanotide injection) for subcutaneous use
What is VYLEESI? VYLEESI is a prescription medicine used to treat hypoactive (low) sexual desire disorder (HSDD) in women who have not gone through menopause, who have not had problems with low sexual desire in the past, and who have low sexual desire no matter the type of sexual activity, the situation, or the sexual partner. Women with HSDD have low sexual desire that is troubling to them. Their low sexual desire is not due to: a medical or mental health problem problems in the relationship medicine or other drug use VYLEESI is not for the treatment of HSDD in women who have gone through menopause or in men. VYLEESI is not for use to improve sexual performance. VYLEESI is not for use in children.
Do not use VYLEESI if you have: high blood pressure that is not controlled (uncontrolled hypertension) known heart (cardiovascular) disease
Before using VYLEESI, tell your healthcare provider about all of your medical conditions, including if you: have high blood pressure. have heart problems. have kidney problems. have liver problems. are pregnant or plan to become pregnant. It is not known if VYLEESI will harm your unborn baby. Pregnancy Registry :There will be a pregnancy registry for women who use VYLEESI during pregnancy. The purpose of this registry is to collect information about the health of you and your baby. Talk to your healthcare provider about how you can take part in this registry or call the VYLEESI Pregnancy Exposure Registry at 800-922-1038. Women who can become pregnant should use effective birth control during treatment with VYLEESI. Talk to your healthcare provider about birth control choices that may be right for you during this time. Stop using VYLEESI and tell your healthcare provider right away if you become pregnant or think you might be pregnant during treatment with VYLEESI. are breastfeeding or plan to breastfeed. It is not known if VYLEESI passes into your breast milk. Talk with your healthcare provider about the best way to feed your baby if you use VYLEESI. Tell your healthcare provider about all the medicines you take, including prescription and over-the-counter medicines, vitamins, and herbal supplements. VYLEESI may affect the way other medicines work, and other medicines may affect the way VYLEESI works. Know the medicines you take. Keep a list of them to show your healthcare provider and pharmacist each time you get a new medicine.
How should I use VYLEESI? See the detailed “ Instructions for Use” that comes with VYLEESI for information on how to prepare and inject a dose of VYLEESI .Talk to your healthcare provider or pharmacist if you have any questions. Use VYLEESI exactly as prescribed by your healthcare provider. VYLEESI comes in an autoinjector that you or your caregiver may use at home to give injections. VYLEESI is given as an injection under the skin (subcutaneous injection), in your thighs or stomach area (abdomen). Inject VYLEESI at least 45 minutes before you think that you will begin sexual activity. Do not inject more than 1 dose of VYLEESI within 24 hours of your last dose. Do not inject more than 8 doses of VYLEESI within a month. Tell your healthcare provider if your symptoms of HSDD have not improved after you have used VYLEESI for 8 weeks.
What are the possible side effects of VYLEESI? VYLEESI can cause serious side effects, including: Temporary increase in blood pressure and decrease in heart rate:An increase in blood pressure and decrease in heart rate can happen shortly after you inject VYLEESI. These changes usually go away within 12 hours after your injection. Increases in blood pressure and an increased risk of heart (cardiovascular) problems can happen if you use VYLEESI more often than prescribed by your healthcare provider. See “How should I use VYLEESI?” Darkening of the skin on certain parts of the body (focal hyperpigmentation) including the face, gums (gingiva) and breast.The chance of darkening of the skin is increased in people with darker skin color. The chance of darkening of the skin is higher if VYLEESI is used every day. Darkening of the skin may not go away, even after you stop using VYLEESI. Tell your healthcare provider if you have any concerns about changes to your skin.
Nausea. Nausea is common and can also be severe. Nausea most commonly happens after the first VYLEESI injection but can also happen after any dose of VYLEESI. The nausea usually lasts for about 2 hours but can last longer in some people. The nausea usually goes away by itself. Tell your healthcare provider if you have nausea that is severe or does not go away. Pre-treatment with the anti-nausea medicine ondansetron was not found to be effective to inhibit or reduce the nausea and is not recommended. Your healthcare provider may prescribe anti-nausea medicine for you to take after nausea occurs. The most common side effects of VYLEESI include:
flushing vomiting hot flush nasal congestion | injection site reactions cough tingling | headache fatigue dizziness
These are not all the possible side effects of VYLEESI. Call your doctor for medical advice about side effects. You may report side effects to FDA at 1-800-FDA-1088.
How should I store VYLEESI? Store at or below 77°F (25°C). Do not freeze. Protect from light. Keep VYLEESI and all medicines out of the reach of children.
General information about the safe and effective use of VYLEESI. Medicines are sometimes prescribed for purposes other than those listed in a Patient Information leaflet. Do not use VYLEESI for a condition for which it was not prescribed. Do not give VYLEESI to other people, even if they have the same symptoms you have. It may harm them. You can ask your healthcare provider or pharmacist for information about VYLEESI that is written for health professionals.
What are the ingredients in VYLEESI? Active ingredient: bremelanotide Inactive ingredients: 2.5% glycerin, sterile water for injection, and hydrochloric acid or sodium hydroxide is added to adjust the pH Marketed By: Cosette Pharmaceuticals, Inc. VYLEESI is a registered trademark of Cosette Pharmaceuticals, Inc. ©2024 Cosette Pharmaceuticals, Inc. All rights reserved. For more information, go to www.VYLEESI.com or call Cosette Pharmaceuticals, Inc. Customer Service at the toll-free number 1-800-922-1038.

Unchanged: Indications and usage, Dosage and administration, Dosage forms and strengths, Contraindications, Warnings and precautions, Adverse reactions, Drug interactions, Overdosage, Description, Clinical pharmacology, Nonclinical toxicology, Clinical studies, How supplied, Instructions for use, Principal Display Panel – 4 Syringe Carton Label, Principal Display Panel – Syringe Label.

Every version

2 versions of set f1d0c1b5-2f39-4bad-a6a4-0066e3ad5dcf, newest first.
VersionPublished on DailyMedCompareSPL file
2Nov 9, 2026Shown belowDownload .zip
1Nov 18, 2025First versionDownload .zip

Read an SPL file

Open an SPL label file

Drop a Structured Product Labeling .xml file, or the .zip DailyMed downloads, to read it as a label. It is read in this browser tab and not uploaded.

Read in this browser tab; nothing is uploaded.

Versions and label text from DailyMed's SPL web services; a version's text is read from its SPL file, so it matches what DailyMed shows. Recent safety-related changes from FDA's Safety-related Labeling Changes database, which covers NDAs and CDER biologics, not generics. Lists refresh daily. DailyMed, National Library of Medicine

About label change history

How to read a comparison

Sections that changed come first, in the order a reviewer reads a label: boxed warning, recent major changes, indications, dosage, contraindications, warnings and precautions, adverse reactions, then the rest. Each shows the changed lines with one unchanged line either side; longer unchanged stretches are folded into a count. Table rows read left to right with cells separated by a bar.

The comparison covers the label text. Images, product data (NDC codes, ingredients, packaging) and formatting are not compared.

Which label is shown

A drug can have several labels: one per brand-name application (Ozempic, Wegovy and Rybelsus are three), and copies from repackagers. For each NDA or BLA the page takes the DailyMed set with the most versions, which is the application holder's. Generic labels are left out; they follow the brand's label.

Frequently asked questions

Where do the versions come from?
DailyMed, the National Library of Medicine's library of labels in Structured Product Labeling (SPL) format. Each time a company submits a revised label, DailyMed publishes it as a new version of the same set and keeps the old ones.
Is a new version a new FDA approval?
Not always. Companies also submit new versions for changes that need no FDA approval first, such as a new address, a new package size or a corrected typo. Safety changes FDA approved are listed in its Safety-related Labeling Changes database, linked below.
Why does the published date differ from the label's revised date?
The published date is when DailyMed posted the version. The label's own revised date, at the end of the highlights, is when the company revised the text, usually a few days to weeks earlier.
How is the comparison made?
Each section is matched by its standard LOINC code, then split into headings, paragraphs, list items and table rows. Lines are aligned with a longest-common-subsequence diff; a removed and an added line that share at least half their words are shown as one edited line with the changed words marked. Curly quotes, dash styles and spacing are ignored.
Is my SPL file uploaded?
No. A file you drop on this page is read in your browser tab and never sent to Arca.
Esc

Type a name: a tool, a company, a drug or brand, a condition, a gene or a state. Identifiers like K231234, NCT05012345 or NDA 215866 open their record.

Logos are each company's own site icon, matched by name through Wikidata, or logos provided by Logo.dev.Company names and logos identify the companies in public FDA and registry records and do not imply endorsement.